In summary, a novel and simple scoring system by integrating sALB with serum ALP, named albumin-to-alkaline phosphatase ratio (AAPR), has been constantly validated as a reliable prognostic indicator across a wide range of malignant tumors, regardless of their treatment options (12, 16–24). Here, ALB is linked to cancer.